We have developed a unique and powerful combination of DNA, RNA and protein analyses that screen more than the usual suspects in solid and/or liquid biopsies.
All the data are integrated into one single report that helps the oncologists in the therapeutic decision-making process.
OncoKDM is an online platform that turns the NGS data of the labs into actionable clinical information.
Moreover, OncoKDM can integrate NGS results with IHC, MSI and TMB data.
The resulting interactive report includes updated information about approved or investigational treatments for each patient.
Our services to biopharma are organised in four pillars: clinical testing, precision enrollment, post-marketing activities and knowledge-driven medicine. We offer NGS and molecular pathology assays, we grant treatment access to patients, we help them to get the treatment reimbursed, and we collect real-world data to support biopharma during discussions with drug agencies and payers.
OncoKDM is an online platform that turns your NGS data into actionable clinical information. Moreover, OncoKDM can integrate NGS results with IHC, MSI and TMB data. The resulting comprehensive and interactive report includes updated information about approved and investigational treatments for each patient, as well as NGS quality control data, patient clinical data and comprehensive NGS variants annotation.
Our platform OncoSHARE shows you the results of your patient's molecular profiling through an online integrated theranostic report that includes a comprehensive biological and clinical interpretation. This report gives you an insight into the most effective treatments according to the unique features of your patient's tumour, taking into account the most relevant scientific information, official cancer guidelines and recruiting clinical trials.
Transforming cancer data into knowledge-driven medicine
Connecting healthcare professionals and patients
We have developed a unique and powerful combination of techniques for therapeutic decision-making: next-generation sequencing of large gene panels, immunohistochemistry analysis and other tests, in solid and/or liquid biopsies.
Our first solution combining DNA, RNA and protein analyses of a tissue biopsy.
A complete solution integrating the analysis of solid and liquid biopsies.
Next-generation sequencing of smart panels with selected key genes per tumor type from a blood sample.
The first personalized liquid biopsy in the market.
Given the expertise of OncoDNA in delivering solutions in precision medicine, we initiated this collaboration with enthusiasm with the aim of developing a specific SOLTI OncoKDM solution integrating any kind of molecular data that might reveal unappreciated vulnerabilities in the tumours of AGATA patients, allowing us to tailor much better their treatment options.
Compared to its competitors, OncoKDM includes patient-centred features that enable oncologists to recommend and make the right treatment decisions according to patient's data and medical history. Moreover, OncoKDM is user-friendly and easy to use, another advantage!
